歐菲光(002456.SZ):醫療內窺鏡產品已實現量產
格隆匯5月6日丨歐菲光(002456.SZ)在互動平臺表示,公司醫療內窺鏡產品已實現量產。公司醫療內窺鏡產品通過研發微型化模組架構,採用鏡頭與CMOS傳感器模塊化設計,融合超薄樹脂精密封裝、超小PAD焊接及一體式灌膠等技術,突破傳統內窺鏡的體積限制和技術瓶頸,具有小型化、解析力穩定、高清晰度、輕薄化、防水化、超微距等顯著優勢,可實現無損成像質量的穩定傳輸,在微創性和多場景適應性已達到行業領先水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.